Clinical trials: Chronic Cough
Chronic Cough
Cough Count Validation
People with respiratory infection, asthmatic patients and cystic fibrosis (CF) patients suffer from a multitude of pathologies of airways and are often inflicted with chronic cough.
- Trial name
- NCT01413698
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- KarmelSonix Ltd.
Post-COVID-19 Syndrome, COVID-19
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset.
- Conditions
- Post-COVID-19 Syndrome, COVID-19, Dyspnea, Fatigue
- Trial name
- NCT06437210
- Testing
- Viusid Oral Solution
- Where
- Colombia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Chronic Cough
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to evaluate the effectiveness of…
- Trial name
- EPICC (NCT01432730)
- Testing
- Gefapixant
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cough
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The study is split into two parts. Part A will assess the safety and tolerability of the new drug.
- Trial name
- FTIH (NCT01494636)
- Testing
- GSK2339345 (solution), GSK2339345 (nebulised), Lidocaine
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis
Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis
A randomized, double-blind, multicenter, active-controlled phase III study to evaluate the efficacy and safety of Levotuss CR tab. in comparison with Levotuss syrup in patients with cough due to acute or chronic bronchitis
- Trial name
- NCT03489837
- Testing
- Levotuss
- Where
- South Korea
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Lung Diseases, Interstitial
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this study is to investigate the correlation between changes from baseline to 52 weeks in Forced Vital Capacity (FVC) [% pred.] and changes from baseline to 52 weeks in dyspnea score [points] or cough…
- Trial name
- NCT05151640
- Testing
- Nintedanib
- Where
- 31 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer
Refractory Chronic Cough
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
- Trial name
- LAKE (NCT07671924)
- Testing
- NAL ER
- Where
- 21 sites in Canada, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Trevi Therapeutics
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Lung Diseases, Interstitial
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough…
- Trial name
- INREAL (NCT04702893)
- Testing
- Nintedanib
- Where
- 21 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Rhinitis
A Study to Investigate the Effect of SB-705498 on Chronic Cough
This study is designed to loook at the affect of oral SB-705498 on cough following an inhaled capsaicin challenge
- Trial name
- NCT01476098
- Testing
- SB-705498
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Chronic Idiopathic Cough
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough.
- Trial name
- NCT02233699
- Testing
- XEN-D0501
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Xention Ltd
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02233686
- Testing
- XEN-D0501
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Xention Ltd
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.
- Trial name
- OCEAN-2 (NCT07868419)
- Testing
- NAL ER
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Trevi Therapeutics
Refractory Chronic Cough
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate [ATP], and distilled…
- Trial name
- NCT02476890
- Testing
- Gefapixant 100 mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cough
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
The primary objectives of this study: To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
- Trial name
- NCT03535168
- Testing
- BAY1902607, Midazolam
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 59 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Chronic Cough
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
- Trial name
- NCT05392192
- Testing
- ADX-629
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cough
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause.
- Trial name
- NCT00506545
- Testing
- SCH 619734
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC